Versor Investments LP Makes New $1.33 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

Versor Investments LP purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,602 shares of the medical research company's stock, valued at approximately $1,328,000.

Other institutional investors also recently made changes to their positions in the company. 1832 Asset Management L.P. raised its position in shares of IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after purchasing an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $70,610,000. Impax Asset Management Group plc increased its position in IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock worth $344,998,000 after buying an additional 264,555 shares during the period. Canada Pension Plan Investment Board raised its stake in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock valued at $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in IQVIA by 285.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock valued at $56,783,000 after acquiring an additional 198,808 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company's stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company's stock.

IQVIA Stock Performance

Shares of IQVIA stock traded down $3.42 during trading on Tuesday, hitting $213.57. 1,981,239 shares of the company's stock traded hands, compared to its average volume of 1,108,328. The business has a 50-day simple moving average of $230.31 and a 200-day simple moving average of $229.04. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $191.45 and a 1 year high of $261.73. The stock has a market capitalization of $38.76 billion, a P/E ratio of 28.48, a PEG ratio of 2.25 and a beta of 1.51.

Analysts Set New Price Targets

Several equities analysts have issued reports on IQV shares. Barclays dropped their price target on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Friday. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Finally, UBS Group lifted their price objective on IQVIA from $295.00 to $300.00 and gave the company a "buy" rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $259.13.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.